DJIA 17,505.73 -177.85 -1.01%
NASDAQ 4,914.92 -77.02 -1.54%
S&P 500 2,051.31 -17.45 -0.84%
market minute promo

Gilead Sciences (NASDAQ: GILD)

113.44 -2.22 (-1.92%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $113.46 -1.90%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $115.95
Previous Close $115.66
Daily Range $113.17 - $116.42
52-Week Range $84.75 - $123.37
Market Cap $166.7B
P/E Ratio 13.17
Dividend (Yield) $1.72 (1.5%)
Ex-Dividend Date
Dividend Pay Date
06/12/15
06/29/15
Volume 3,061,037
Average Daily Volume 10,864,318
Current FY EPS $11.04

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary Rss Feed

Gilead Sciences Gets Another Green Light in Japan

Gilead Sciences' Hepatitis C drug Harvoni gets approval for sale in Japan. Will that be meaningful to the company's future?

'Wisdom Of Experts' Portfolio: Mid-Year 2015 Update

Gilead's TAF-Based Drugs Or ViiV-GSK's Triumeq, Which Is Better?

Keep An Eye On These 8 After-Hours Movers

Gilead's (GILD) HCV Drug Harvoni Gets Approval in Japan - Analyst Blog

After Hours Most Active for Jul 6, 2015 : ABBV, INFY, RAD, CAG, GILD, INTC, SFM, SFUN, BNDX, PPC, M

After Hours Most Active for Jul 6, 2015 : ABBV, INFY, RAD, CAG, GILD, INTC, SFM, SFUN, BNDX, PPC, MBI, MU

Japan's Ministry Of Health Approval Of Harvoni Offers Additional Growth Prospects To Gilead Sciences

Gilead Sciences is Still Undervalued

Gilead Sciences Spent $125 Million to Get This Drug on the Market 4 Months Early

It's all about the switching.

Is Gilead Headed Lower From Here?

See More GILD News...

GILD's Top Competitors

GILD $113.44 (-1.92%)
Current stock: GILD
AMGN $152.98 (-0.98%)
Current stock: AMGN
CELG $117.45 (-1.15%)
Current stock: CELG
$0.00 (0.00%)
Current stock: